Pacira Pharmaceuticals (NASDAQ:PCRX) reported Q1 2018 earnings this Morning, coming in at $0.02 per share, in-line Wall Street’s estimates of $0.02 per Share. Revenue for the quarter came in at $74.61 million beating analyst estimates of $73.92 million Recent Insider Trading for Pacira Pharmaceuticals (NASDAQ:PCRX)
- On 1/10/2018 David M. Stack, CEO, sold 28,885 with an average share price of $40.19 per share and the total transaction amounting to $1,160,888.15.
- On 12/15/2017 Lauren Bullaro Riker, VP, sold 340 with an average share price of $43.70 per share and the total transaction amounting to $14,858.00.
- On 11/20/2017 James B. Jones, SVP, sold 850 with an average share price of $41.11 per share and the total transaction amounting to $34,943.50.
- On 11/17/2017 Kristen Marie Williams, CAO, sold 10,000 with an average share price of $40.00 per share and the total transaction amounting to $400,000.00.
- On 11/15/2017 David M Stack, CEO, sold 58,885 with an average share price of $38.34 per share and the total transaction amounting to $2,257,650.90.
- On 11/10/2017 Mark A Kronenfeld, Director, bought 1,000 with an average share price of $41.60 per share and the total transaction amounting to $41,600.00.
Dividend History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Recent Trading for Pacira Pharmaceuticals (NASDAQ:PCRX) Shares of Pacira Pharmaceuticals closed the previous trading session at 32.05 down -2.33 6.76% with 31.950000762939453 shares trading hands.